PepGen

We are looking forward to reporting preliminary data from the 5 mg/kg cohort of our CONNECT1 trial in DMD, expected mid-year. This will be followed with preliminary data from the higher 10 mg/kg dose cohort, further advancing our goal of transforming the treatment landscape for DMD. https://lnkd.in/ensfjvrF

We are excited to announce the expansion of our executive team with the appointments of Afsaneh Mohebbi, PhD as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA as Senior Vice President, Investor Relations and Corporate Communications.   Their experience will enhance PepGen’s expertise in critical areas of the organization, and we eagerly anticipate their contributions as we prepare for numerous key clinical milestones in the second half of this year.   https://lnkd.in/eXBwvhfA

Congratulations Hayley Parker, SVP of Global Regulatory Affairs, for being selected as one of Endpoints News’ LGBTQ+ Leaders in Biopharma ’24. It is an honor to have Hayley as part of our PepGen team, where she has been an integral player in promoting our inclusive work environment.   Hayley is one of 15 biopharma leaders honored this year. We want to take a moment to thank each of these individuals for helping make the biotech industry more welcoming for the LGBTQ+ community. Read more here: https://lnkd.in/gSEAt4s6     Join the Endpoints team this morning at 11am ET for a virtual event to celebrate and hear insights from this year’s honorees. Register here: https://lnkd.in/eE8eBWCQ #HappyPrideMonth

We can’t wait for the beautiful scenery and special moments Camp Promise - Rockies brings each year! ⛰️ To help provide a great camp experience, we ask for your support in obtaining items from our Amazon Wish List. Support or share: https://lnkd.in/eYACR2Vf

Meet Sejal Batra, MS, Clinical Project Manager here at PepGen. Sejal plays a crucial role in ensuring that our CONNECT1 clinical trial for DMD is conducted effectively, on schedule while maintinaing compliance with regulations and protocols. To learn more about our team visit: https://bit.ly/48UJ8Ch

We are one week away from the PPMD’s 30th Annual Conference! PepGen is excited to attend another engaging conference hosted by Parent Project Muscular Dystrophy. For more info: https://bit.ly/4bYps1s

#ICYMI PepGen’s VP, Clinical Science, Jane Larkindale, participated in #EuroDyma Pharma's Day last month where she provided an update on our FREEDOM-DM1 study. To watch, click https://bit.ly/4bE7YYq  #myotonic #DM1

PepGen is thrilled to announce the promotion of Michelle Mellion, MD to Chief Medical Officer and Hayley Parker, PhD to SVP, Global Regulatory Affairs. Since joining PepGen, both leaders have played integral roles in driving both our clinical and regulatory strategies. Please join us in congratulating them! https://lnkd.in/emxN3bhp

We're hiring a Senior Director, Regulatory Strategist – Global Regulatory Lead! Join our team to drive global regulatory strategies and ensure compliance across diverse markets. bit.ly/45gFz8r

PepGen thanks CureDuchenne for the opportunity to join the #DMD community at the #FUTURES conference. We always feel privileged to engage with advocates, families, researchers, and clinicians in meaningful discussions on how we can support the DMD community.